On September 11, METIS TECHBIO-P fell 5.17% in regular trading, trading at HK$16.40, with turnover of HK$15.81 million. The stock extended its pullback for a second consecutive session as short-term profit-taking intensified.
Since its formal inclusion in the Stock Connect eligible securities list on September 7, METIS TECHBIO-P had accumulated gains exceeding 40% within just three trading days, driven by unlocked southbound capital access and a strategic cooperation agreement with Greenleaf Pharmaceutical on AI-powered drug delivery. The rapid run-up created significant short-term profit overhang, with the stock already retreating over 5% in the prior session.
The broader biotechnology sector continued to trade weak, adding further downside pressure. Within the sector, INNOVENT BIO fell 1.75%, AKESO declined 2.19%, BEONE MEDICINES dropped 1.84%, and HBM HOLDINGS-B slid 4.44%, reflecting subdued sector-wide sentiment. Market participants appear to be locking in gains from the post-inclusion rally amid a risk-off tone across the biotech space.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)